Objective response after immune checkpoint inhibitors in a chemotherapy-refractory pMMR/MSS metastatic rectal cancer patient primed with experimental AlloStim® immunotherapy
Article in Translational Medicine Communications (May 2024)
The most recent citing publications are shown below. View all 7 publications that cite this research output on Dimensions.
JAML inhibits colorectal carcinogenesis by modulating the tumor immune microenvironment
Article in In Vitro Cellular & Developmental Biology - Animal (April 2024)
Objective Response after Immune Checkpoint Inhibitors in a Chemotherapy-Refractory pMMR/MSS Metastatic Rectal Cancer Patient Primed with Experimental AlloStim® Immunotherapy.
Preprint in Research Square (April 2024)